Yes, Loxo is still planning on seeking an accelerated OK, in case you had forgotten
Back in the spring, Loxo Oncology $LOXO was ready to pounce with an early snapshot of some clinical responses to its lead cancer drug, a common strategy among small public biotechs looking to raise their profile – and cash. Not surprisingly, it also immediately mapped out a plan to set up its Phase II study as a registrational study, SOP among biotechs capitalizing on the FDA’s open arms for quick approvals, when the early data are right.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.